TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers

TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers

Overview

Target Knowledge Gap: FTD Gap #1: "What determines whether TDP-43 vs tau pathology develops in GRN vs MAPT mutation carriers?" (Score: 33/40) — Both GRN and MAPT mutations cause FTD but produce different pathologies. Understanding the molecular switch could enable pathology-specific therapies.

Disease: Frontotemporal Dementia (FTD) Priority Rank: 1 (Tier 1: Critical)

Rationale

Approximately 10-15% of FTD cases are caused by GRN (progranulin) or MAPT (tau) gene mutations. Despite both causing FTD:

• GRN mutations → TDP-43 pathology (FTLD-TDP)
• MAPT mutations → Tau pathology (FTLD-tau)

The fundamental question is: what molecular mechanisms determine which pathology develops? Understanding this "fate switch" could:

Enable targeted therapy development for each pathology type

Reveal whether pathology conversion is possible

Identify protective mechanisms applicable to both

Hypothesis

The pathology type is determined by a combination of:

Loss-of-function vs gain-of-function: GRN haploinsufficiency causes TDP-43 pathology through loss of nuclear TDP-43 function; MAPT mutations cause tau pathology through toxic gain-of-function

Cellular stress responses: Different cellular stress pathways trigger aggregation of either TDP-43 or tau

Post-translational modification patterns: PTM signatures that favor one aggregation pathway over another

Experimental Design

...

TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers

Overview

Target Knowledge Gap: FTD Gap #1: "What determines whether TDP-43 vs tau pathology develops in GRN vs MAPT mutation carriers?" (Score: 33/40) — Both GRN and MAPT mutations cause FTD but produce different pathologies. Understanding the molecular switch could enable pathology-specific therapies.

Disease: Frontotemporal Dementia (FTD) Priority Rank: 1 (Tier 1: Critical)

Rationale

Approximately 10-15% of FTD cases are caused by GRN (progranulin) or MAPT (tau) gene mutations. Despite both causing FTD:

• GRN mutations → TDP-43 pathology (FTLD-TDP)
• MAPT mutations → Tau pathology (FTLD-tau)

The fundamental question is: what molecular mechanisms determine which pathology develops? Understanding this "fate switch" could:

Enable targeted therapy development for each pathology type

Reveal whether pathology conversion is possible

Identify protective mechanisms applicable to both

Hypothesis

The pathology type is determined by a combination of:

Loss-of-function vs gain-of-function: GRN haploinsufficiency causes TDP-43 pathology through loss of nuclear TDP-43 function; MAPT mutations cause tau pathology through toxic gain-of-function

Cellular stress responses: Different cellular stress pathways trigger aggregation of either TDP-43 or tau

Post-translational modification patterns: PTM signatures that favor one aggregation pathway over another

Experimental Design

Study Design

Multi-center, multi-omics comparative study of GRN and MAPT mutation carriers

Model Systems

Primary: Induced pluripotent stem cells (iPSCs) from GRN and MAPT mutation carriers → differentiated cortical neurons

Secondary: Patient-derived brain tissue from FTD autopsy cases (GRN vs MAPT)

Validation: CRISPR-corrected iPSC lines to confirm mutation-specific effects

Sample Size

• iPSC lines: 10 GRN carriers, 10 MAPT carriers, 10 non-carrier controls
• Brain tissue: 30 FTLD-TDP (GRN), 30 FTLD-tau (MAPT), 30 controls

Methods

Multi-Omics Profiling

| Layer | Technique | Readout |
|-------|-----------|---------|
| Transcriptomics | Single-nucleus RNA-seq | Cell-type specific gene expression changes |
| Proteomics | Quantitative MS (TMT-labelled) | Protein abundance and PTM patterns |
| Phosphoproteomics | Phospho-enrichment MS | Kinase activation signatures |
| Interactomics | Proximity-dependent biotinylation (BioID) | Protein-protein interaction networks |

Key Analyses

Comparative analysis of GRN vs MAPT neurons:

• Identify differentially expressed genes and proteins
• Map pathway activation differences
• Compare stress response signatures

TDP-43 phosphorylation analysis:

• pSer409/410 TDP-43 levels in GRN vs MAPT neurons
• Kinases/phosphatases regulating TDP-43 phosphorylation

Tau isoform analysis:

• 3R vs 4R tau ratio in MAPT vs GRN neurons
• Post-translational modifications (phosphorylation, acetylation)

Nuclear vs cytoplasmic localization:

• TDP-43 mislocalization in GRN neurons
• Nuclear import/export alterations

Expected Outcomes

Primary

Molecular signature distinguishing GRN vs MAPT pathology:

• Identified signaling pathways specific to each pathology type
• Validated biomarker panel for pathology prediction

Fate-switch mechanism identified:

• Single factor or combination that determines pathology type
• Potential intervention points for pathology conversion

Secondary

iPSC disease model validation (reproduces human pathology)

Drug target identification for each pathology type

Biomarker panel for patient stratification in clinical trials

Feasibility Assessment

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Technical Feasibility | 8/10 | iPSC technology mature; single-nucleus seq standard |
| Timeline | 24 months | 6 mo iPSC derivation, 12 mo profiling, 6 mo analysis |
| Cost | $2.5M | iPSC lines ($500K), omics ($1.5M), personnel ($500K) |
| Data Availability | 7/10 | Existing iPSC banks; autopsy tissue from many centers |

Risk Assessment

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Insufficient differentiation | Medium | Optimize cortical neuron protocol |
| Batch effects in omics | High | Use standardized pipelines, include controls in each batch |
| Limited brain tissue | Medium | Multi-center collaboration (UCSF, Mayo, Cambridge) |

Comparison to Existing Research

• DIAN-TU: Focuses on AD; FTD-specific studies needed
• ARTFL/LEFFTDS: Clinical network exists; could enable tissue sharing
• Previous iPSC studies: Limited to single-gene comparisons; this is first systematic multi-omics

Research Team Requirements

| Role | Institution | Expertise |
|------|-------------|-----------|
| Lead PI | UCSF (Adam Boxer) | FTD clinical trials, GRN biology |
| iPSC differentiation | Stanford (Mali) | Neural differentiation |
| Proteomics | UCLA (Cotta) | MS-based proteomics |
| Bioinformatics | UCSF (Yokomori) | Single-cell analysis |

Relevance to Therapy Development

Target identification: Pathways specific to each pathology could yield targeted drugs

Patient stratification: Biomarkers to select patients for pathology-specific trials

Mechanistic validation: Confirm mechanisms before expensive clinical programs

Cross-References

• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — Primary disease
• [TDP-43 Pathology](/mechanisms/tdp-43-pathology) — TDP-43 aggregation
• [Tau Pathology](/mechanisms/tau-pathology) — Tau aggregation
• [GRN Gene](/genes/grn) — Progranulin gene
• [MAPT Gene](/genes/mapt) — Tau gene
• [FTD TDP-43](/mechanisms/ftd-tdp-43-pathology) — TDP-43 pathway
• [FTD Biomarkers](/biomarkers/ftd-biomarkers) — Diagnostic markers

References

[Rascovsky K, et al, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011)](https://pubmed.ncbi.nlm.nih.gov/21810889/)

[Boxer AL, et al, Advancing research and treatment for frontotemporal lobar degeneration (ARTFL) (2019)](https://pubmed.ncbi.nlm.nih.gov/31683156/)

[Rohrer JD, et al, The heritability and genetics of frontotemporal lobar degeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/1982288/)

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers discovered through SciDEX knowledge graph analysis: